The aromatase enzyme is expressed not only in BC tissue but also in bone tissue [9], thus, AIs could lead to a lower bone mineral density (BMD) with a resulting increased risk of incident fragility fractures, leading to the well-known condition defined as cancer treatment-induced bone loss (CTIBL) [10,11]. The gene discussed is CYP19A1; the disease is breast cancer.